Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 1

3(42.9%)

7Total

N/A(4)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05381038Phase 1Recruiting

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Role: collaborator

NCT04522284Phase 1Unknown

PRECISE CURATE.AI Pilot Clinical Trial

Role: collaborator

NCT05175235Phase 1Unknown

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

Role: collaborator

NCT05083676Not ApplicableCompleted

A Study Protocol on Peer Digital Acceset (PDA)

Role: lead

NCT05199675Not ApplicableUnknown

Implementing Digital Peer Support Training for Adolescent Mental Health

Role: lead

NCT04848935Not ApplicableUnknown

CURATE.AI COR-Tx Trial for Post Brain Radiotherapy Patients

Role: collaborator

NCT04357691Not ApplicableUnknown

Effects of Different Cardiorespiratory Training Program on Endurance Performance

Role: collaborator

All 7 trials loaded